Our pilot programme is strategically designed to validate QDx’s ability to detect early metabolic drift across three of the most burdensome chronic conditions: Asthma, Type 2 Diabetes, and Coronary Heart Disease. These conditions were selected based on strong clinical relevance, data availability, and their distinct progression pathways allowing us to rigorously test the QDx engine across diverse physiological systems.

This proof-of-principle phase focuses on simulating ultra-early physiological changes before standard diagnostics detect them using our proprietary hybrid Quantum–AI framework.